NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma

NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma

IntoroductionNuclear receptor subfamily 2 group F member 6 (NR2F6) is a promising checkpoint target for cancer immunotherapy. However, there has been no investigation of NR2F6 in glioma. Our study systematically explored the clinical characteristics and biological functions of NR2F6 in gliomas.Metho...

Full description

Bibliographic Details
Main Authors: Hayat Miftah, Oumayma Naji, Saadia Ait Ssi, Amina Ghouzlani, Abdelhakim Lakhdar, Abdallah Badou
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
NR2F6
glioma
immunotherapy
glioma progression
immune and stromal infiltration
immunosuppression
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1139268/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1139268/full

Similar Items